Events & Webinars

Imagion Chats with 180 Markets on the Future of Cancer Detection
Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging
Cleansing Notice – Entitlement Offer Shares
This notice is given by Imagion Biosystems Limited (the ‘Company’ or ‘IBX’) under section 708AA(2)(f) of the Corporations Act 2001 (Cth) (‘Corporations Act’) as modified
Non-renounceable Entitlement Offer
MELBOURNE – Imagion Biosystems (ASX:IBX, Imagion or the Company), a company dedicated to improving healthcare through the early detection of cancer, today advises that it
Imagion Funding Update
Highlights: Shareholder entitlement offer seeking to raise up to $2.4 million Funding facility of up to $15 million secured with Mercer Street Global Opportunity Fund,
Imagion Secures Growth Funding
Highlights: Imagion secures a funding facility of up to $15 million to support next phase of clinical and oncology pipeline development Funding Facility includes: $1.5 million
Imagion Receives 2nd CSIRO Federal Government Grant for Prostate Cancer Project
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it
Imagion Biosystems 2022 Annual Report
Imagion Biosystems has released its Annual Report for the year ending 31 December 2022. [See linked documents below] 2022 Research & Development Highlights: March 2022
Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
Biotech Daily — Imagion Trial Review Backs Magsense for All Cancer MRI
“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners. Imagion said that
Positive independent review sets priority path to market for MagSense® Technology
https://www.youtube.com/watch?v=g8SnQWwJh68 Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic
Quarterly Activity Report – Quarter Ending 31 December 2022
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Imagion presents MagSense® interim study results at breast cancer meeting
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of
Quarterly Activity Report – Quarter Ending 30 September 2022
Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion
Imagion Biosystems receives AU$2.5 million in R&D tax incentives
ASX Announcement: MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report
The Market Herald Interview Discussing First-of-its-Kind Magnetic Imaging Technology
We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the technology has
Fear and Greed Podcast Discussing Precise Imaging Solutions to Detect Cancers
Our Chairman and CEO Bob Proulx was a recent guest at the Fear and Greed podcast, discussing our pursuit of better, more precise imaging solutions to
2022 Switzer Small & Micro Cap Conference Presentation
Imagion Bio CEO, Robert Proulx, presents company information to investors at the 2022 Switzer Small & Micro Cap Conference in September. Video Transcript: Thank you,
Imagion to Present Prostate Cancer Research Data at WMIC 2022
https://youtu.be/iH0a08glQYo Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion
Half-Year Results for the First Half of 2022 and Appendix 4D
Today, we released our Appendix 4D and Half-Year Financial Report for the half-year ending 30 June 2022 to the ASX. 1H2022 Highlights: MagSense® HER2 breast
Quarterly Activity Report and Appendix 4C for 30 June 2022
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2022. The announcement highlights: MagSense® HER2 imaging agent
Iron Oxide Nanoparticles in Lipid Delivery System May Lead to Better Cancer Treatment
Lipids are frequently used to form drug carrying nanoparticles because of their favorable biocompatibility. However, construction of such drug-carrying lipid nanoparticles often involves multiple steps.
Q&A Session at 2022 Annual General Meeting
Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems’ board of directors answer questions from shareholders at the AGM
Results of 2022 Annual General Meeting
In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Imagion Biosystems Limited advises the results of its Annual General
Presentation Visuals from 25th May 2022 Annual General Meeting
The presentation visuals from the 25th May 2022 Annual General Meeting are now available. You can find the 2022 AGM Investor Presentation here. Other
Watch the latest recorded presentations and webinars
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.